Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy Assisted Corneal Transplantation in the Treatment of Refractory Viral Keratitis

NCT04560790 is registered in ClinicalTrials.gov with Shanghai BDgene Co., Ltd. as lead sponsor.

NCT NCT04560790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy Assisted Corneal Transplantation in the Treatment of Refractory Viral Keratitis
Lead sponsor
Shanghai BDgene Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
November 4, 2020
Completion date
July 5, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blindness eye, cornea, herpes simplex virus infection, viral keratitis